Methods of treating musculoskeletal deformities of an anatomical structure in a quadruped animal with botulinum toxin are described. Such deformities can be rotational or flexural. Such deformities can be acquired or congenital. Such anatomical structures include a limb, neck, torso, and/or pelvis of the quadruped animal.

The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.

A compound of formula (I) R.sub.1-W.sub.m-X.sub.n-AA.sub.1-AA.sub.2-AA.sub.3-AA.sub.4-AA.sub.5-AA.sub.6-Y.sub.p-Z.sub.q-R.sub.2, a stereoisomer and/or cosmetically acceptable salt thereof, and a method of treatment using the compound are described. In the compound, AA.sub.1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA.sub.2 is Val, Ile, Leu or Ala; AA.sub.3 is Tyr, Phe, Trp, Lys, Arg or His; AA.sub.4 is Lys, Arg, His, Pro or Val; AA.sub.5 is Asn, Asp, Gln or no amino acid; AA.sub.6 is Thr, Ala, Ser or no amino acid. The compounds are useful for the treatment of the symptoms of skin aging and, in particular, for the treatment of skin wrinkles, the treatment of a sagging appearance of the skin, and/or the reduction of facial asymmetry.

A compound of formula (I) R.sub.1-W.sub.m-X.sub.n-AA.sub.1-AA.sub.2-AA.sub.3-AA.sub.4-AA.sub.5-AA.sub.6-Y.sub.p-Z.sub.q-R.sub.2, a stereoisomer and/or cosmetically acceptable salt thereof, and a method of treatment using the compound are described. In the compound, AA.sub.1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA.sub.2 is Val, Ile, Leu or Ala; AA.sub.3 is Tyr, Phe, Trp, Lys, Arg or His; AA.sub.4 is Lys, Arg, His, Pro or Val; AA.sub.5 is Asn, Asp, Gln or no amino acid; AA.sub.6 is Thr, Ala, Ser or no amino acid. The compounds are useful for the treatment of the symptoms of skin aging and, in particular, for the treatment of skin wrinkles, the treatment of a sagging appearance of the skin, and/or the reduction of facial asymmetry.

A syringe assembly for administration of a neurotoxin, the syringe assembly comprising: a syringe comprising: a clear syringe barrel with dosage markings completely encircling the clear syringe barrel; and a plunger having a plunger body and a clear inverted plunger tip; and a needle assembly comprising a needle and a sealing hub for removably attaching the needle assembly to the syringe, wherein the needle is approximately 0.15 inches to approximately 0.3 inches in length and has a gauge of approximately 27 gauge to approximately 35 gauge.

A protease directed to a non-neuronal SNARE protein is described. The protease is produced by selective mutation of a botulinum neurotoxin light chain, and is characterized utilizing a reporting construct that includes all or part of the non-neuronal SNARE protein. Such a protease has utility in the treatment of diseases associated with hypersecretion, where the hypersecretion is mediated by a non-neuronal SNARE protein.

This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.

A method for treating chronic kidney disease, or other renal conditions that has resulted in chronic low-grade activation of the cytokine system in a patient that is in need. Thereof comprising administering botulinum toxin to mitigate the inflammatory state in the kidney. A method of treating acute kidney disease that has resulted from an acute activation of the cytokine system in a patient in need thereof comprising administering nitrous oxide or any inhaled anesthetic in amounts, concentrations, and durations needed to control cytokines and mitigate further damage to healthy kidney tissue.